Quarterly report pursuant to Section 13 or 15(d)

Other current assets (Tables)

v3.24.3
Other current assets (Tables)
9 Months Ended
Sep. 30, 2024
Other current assets  
Summary of other current assets

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31, 

​

    

2024

​

2023

Research and development credits receivable

 

$

24,905

​

$

46,098

Prepayments

 

​

14,164

​

​

9,954

Clinical materials

 

​

97

​

​

1,329

VAT receivable

​

​

1,209

​

​

—

Other current assets

 

​

3,375

​

​

2,412

​

​

$

43,750

​

$

59,793